<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Zeel mehta on Medium]]></title>
        <description><![CDATA[Stories by Zeel mehta on Medium]]></description>
        <link>https://medium.com/@zeelm1995?source=rss-5aba8f943c16------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*lPGPKvDGL-Zu52i-.jpg</url>
            <title>Stories by Zeel mehta on Medium</title>
            <link>https://medium.com/@zeelm1995?source=rss-5aba8f943c16------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Wed, 18 Nov 2026 19:53:56 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@zeelm1995/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Emerging Paradigms in Diagnosis and…]]></title>
            <link>https://medium.com/@zeelm1995/interstitial-cystitis-bladder-pain-syndrome-ic-bps-emerging-paradigms-in-diagnosis-and-de31d734a4b0?source=rss-5aba8f943c16------2</link>
            <guid isPermaLink="false">https://medium.com/p/de31d734a4b0</guid>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[intervention]]></category>
            <category><![CDATA[urology]]></category>
            <category><![CDATA[nephrology]]></category>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Zeel mehta]]></dc:creator>
            <pubDate>Tue, 22 Apr 2025 14:34:15 GMT</pubDate>
            <atom:updated>2025-04-22T14:38:34.541Z</atom:updated>
            <content:encoded><![CDATA[<h3>Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS): Emerging Paradigms in Diagnosis and Multimodal Management</h3><p>Zeel Mehta, M.S.Pharm | Medical Writer: Urology/Nephrology</p><h3>Executive Summary</h3><p>Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic, often debilitating urological condition characterized by pelvic pain, urinary urgency, and frequency in the absence of infection or other identifiable causes. Historically underdiagnosed and mismanaged, IC/BPS presents a complex interplay of urothelial dysfunction, neurogenic inflammation, and psychosocial factors. This article explores the latest diagnostic frameworks, pathophysiological insights, and innovative multimodal treatment strategies, emphasizing patient-centered care and interdisciplinary collaboration.</p><h3>Introduction</h3><p>IC/BPS affects up to 6.5% of women and 2.3% of men globally, yet remains poorly understood in both clinical and research settings. Often mistaken for recurrent UTIs, overactive bladder, or gynecological conditions, its diagnosis is one of exclusion. Emerging paradigms are redefining IC/BPS as a heterogeneous syndrome requiring nuanced diagnostic approaches and tailored therapeutic regimens.</p><h3>Diagnostic Challenges and Innovations</h3><h4>Differential Diagnosis</h4><ul><li>Rule out urinary tract infections, bladder cancer, sexually transmitted infections, endometriosis, and overactive bladder.</li></ul><p><strong>Tools and Techniques</strong></p><ul><li><strong>Cystoscopy with Hydrodistension</strong>: Useful for identifying Hunner lesions.</li><li><strong>Voiding Diaries</strong>: Offer non-invasive insight into symptom patterns.</li><li><strong>Pain Scales and Symptom Questionnaires</strong>: Validated tools like the O’Leary-Sant index.</li><li><strong>Biomarkers (Emerging)</strong>: Antiproliferative factor (APF), nerve growth factor (NGF), and urinary cytokines.</li></ul><h3><strong>Pathophysiological Insights</strong></h3><ul><li><strong>Urothelial Dysfunction</strong>: Disruption in glycosaminoglycan (GAG) layer leading to increased permeability.</li><li><strong>Neurogenic Inflammation</strong>: Upregulation of mast cells and sensory nerve endings.</li><li><strong>Central Sensitization</strong>: Chronic pain circuitry involving the spinal cord and brain.</li></ul><h3>Multimodal Management Strategies</h3><h4>Stepwise Treatment Model (AUA Guidelines)</h4><ol><li><strong>Behavioral Modification</strong>: Fluid management, diet changes, bladder training.</li><li><strong>Physical Therapy</strong>: Pelvic floor muscle relaxation, myofascial release.</li><li><strong>Oral Medications</strong>: Amitriptyline, pentosan polysulfate, antihistamines.</li><li><strong>Intravesical Therapy</strong>: Heparin, lidocaine, DMSO.</li><li><strong>Neuromodulation</strong>: Sacral nerve stimulation, posterior tibial nerve stimulation.</li><li><strong>Surgery</strong>: Rare, reserved for severe refractory cases.</li></ol><h4>Emerging Therapies</h4><ul><li><strong>Intravesical Liposomes</strong>: To restore urothelial barrier.</li><li><strong>Monoclonal Antibodies</strong>: Targeting nerve growth factors.</li><li><strong>Cannabinoids</strong>: Investigational, for pain relief and anti-inflammatory effects.</li></ul><h3>Patient Case Vignette</h3><p><em>“Anna,” a 34-year-old teacher, presents with a 2-year history of bladder pain and urinary urgency, previously misdiagnosed as recurrent UTIs. Cystoscopy reveals no Hunner lesions. A multidisciplinary plan involving pelvic floor therapy, dietary adjustments, and oral amitriptyline yields significant symptom relief within 8 weeks.</em></p><h3>Interdisciplinary Collaboration</h3><ul><li><strong>Urologist</strong>: Diagnostic and interventional oversight.</li><li><strong>Pelvic Floor Physical Therapist</strong>: Core component of non-pharmacologic management.</li><li><strong>Pain Specialist</strong>: For neuromodulatory strategies.</li><li><strong>Dietitian</strong>: To guide elimination and anti-inflammatory diets.</li><li><strong>Psychologist</strong>: CBT and mindfulness strategies to manage chronic pain and anxiety.</li></ul><h3><strong>Conclusion</strong></h3><p>IC/BPS demands a comprehensive, individualized approach rooted in emerging science and holistic care. As understanding of its multifactorial nature deepens, medical writers and clinicians alike have a vital role in disseminating nuanced, empathetic, and up-to-date information. Future research and guideline updates will continue to reshape the landscape, but patient-centered multimodal care remains the cornerstone of effective management.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*yCk8DnaRefd1GUpaF9ZCFA.png" /><figcaption>Understanding Interstitial Cystitis/Bladder Pain Syndrome: A Visual Guide to Diagnostic Challenges, Pathophysiology, and Multimodal Management Approaches.</figcaption></figure><h3>References</h3><ol><li>Hanno PM et al. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. AUA Guideline. J Urol. 2014.</li><li>Nickel JC. Interstitial Cystitis: A Chronic Inflammatory Bladder Condition. Med Clin North Am. 2018.</li><li>Clemens JQ et al. The MAPP Research Network: New Perspectives on IC/BPS. Nat Rev Urol. 2014.</li><li>Engeler D et al. Guidelines on Chronic Pelvic Pain. EAU. 2022.</li><li>Parsons CL. The Role of the GAG Layer in IC/BPS. Urology. 2011.</li></ol><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=de31d734a4b0" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[The Gut-Kidney Axis: Exploring Microbiome Dysbiosis in CKD Progression]]></title>
            <link>https://medium.com/@zeelm1995/the-gut-kidney-axis-exploring-microbiome-dysbiosis-in-ckd-progression-280e27f73aee?source=rss-5aba8f943c16------2</link>
            <guid isPermaLink="false">https://medium.com/p/280e27f73aee</guid>
            <category><![CDATA[probiotics]]></category>
            <category><![CDATA[nephrology]]></category>
            <category><![CDATA[chronic-kidney-disease]]></category>
            <category><![CDATA[dysbiosis]]></category>
            <category><![CDATA[microbiome]]></category>
            <dc:creator><![CDATA[Zeel mehta]]></dc:creator>
            <pubDate>Tue, 22 Apr 2025 09:18:43 GMT</pubDate>
            <atom:updated>2025-04-22T09:18:43.657Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Published: April 2025<br>By Zeel Mehta| Medical Writer — Nephrology &amp; Microbiome Science</em></p><h3>🧠 What Is the Gut-Kidney Axis?</h3><p>The human gut microbiota is a powerhouse of biochemical activity. But did you know it also plays a surprising role in kidney health?</p><p>The <strong>“gut-kidney axis”</strong> is a two-way communication system between your digestive tract and your kidneys. In people with <strong>Chronic Kidney Disease (CKD)</strong>, this link becomes disrupted — leading to an unhealthy gut, toxin buildup, and accelerated kidney damage.</p><p>This article unpacks the science behind this emerging field, explains how gut microbes affect kidney function, and explores the future of CKD management through microbiome therapy.</p><h3>🔄 How the Gut and Kidneys Influence Each Other</h3><p>It’s a <strong>two-way street</strong>:</p><ul><li><strong>CKD affects the gut</strong> by altering pH, slowing motility, and disturbing immune responses — all of which foster harmful bacterial growth.</li><li><strong>The gut affects CKD</strong> by producing <strong>toxins</strong> that would normally be filtered out by healthy kidneys. In CKD, these toxins accumulate and worsen inflammation.</li></ul><blockquote><strong><em>Key Concept</em></strong><em>: Dysbiosis = an imbalance in gut bacteria that contributes to disease progression.</em></blockquote><p>📚 <em>Vaziri ND et al., Kidney Int. 2013</em></p><h3>⚠️ Toxic Metabolites to Know</h3><p>Gut bacteria metabolize food components — especially proteins — into harmful substances when kidney function is compromised. Three major toxins are:</p><h3>1. Indoxyl Sulfate</h3><ul><li>🧬 From: Tryptophan metabolism</li><li>❗ Effect: Increases oxidative stress, causes fibrosis</li></ul><h3>2. p-Cresyl Sulfate</h3><ul><li>🧬 From: Tyrosine and phenylalanine metabolism</li><li>❗ Effect: Increases cardiovascular risk in CKD</li></ul><h3>3. TMAO (Trimethylamine N-oxide)</h3><ul><li>🧬 From: Choline and carnitine-rich foods</li><li>❗ Effect: Accelerates kidney and heart disease</li></ul><p>📚 <em>Niwa, 2010 | Vanholder et al., 2003 | Tang et al., 2015</em></p><h3>🧪 Signs of Dysbiosis in CKD Patients</h3><ul><li>🔻 Reduced microbial diversity</li><li>🚨 High levels of urease-, uricase-, and indole-producing bacteria</li><li>🔓 “Leaky gut” — increased intestinal permeability leading to chronic inflammation</li></ul><p>📚 <em>Ramezani &amp; Raj, JASN 2014</em></p><h3>💡 Microbiome-Based Interventions: What’s on the Horizon?</h3><p>While early in development, targeting the gut microbiome in CKD is showing promise. Here’s what’s being explored:</p><h3>✅ Probiotics &amp; Prebiotics</h3><p>Restore microbial balance and reduce production of uremic toxins (📚 <em>Koppe L et al., 2015).</em></p><h3>✅ Dietary Changes</h3><p>High-fiber, plant-rich diets feed beneficial bacteria (📚 <em>Krishnamurthy et al., 2012).</em></p><h3>✅ Oral Adsorbents (e.g., AST-120)</h3><p>Bind toxins in the gut to limit systemic accumulation (📚 <em>Miyazaki et al., 2000).</em></p><h3>🧬 Fecal Microbiota Transplantation (FMT)</h3><p>Still experimental, but may reset gut health in CKD (📚 <em>Wang et al., 2020).</em></p><h3>🚧 Challenges to Watch</h3><ul><li>🔄 High inter-individual variability in gut microbiota</li><li>⚠️ Lack of clinical standardization</li><li>📊 More randomized controlled trials are needed</li></ul><p>Despite these challenges, gut-focused interventions are gaining traction as a complementary approach in CKD care.</p><h3>✅ Key Takeaways</h3><ul><li>The <strong>gut-kidney axis</strong> plays a central role in the progression of CKD.</li><li>Gut microbial <strong>dysbiosis</strong> contributes to toxin buildup and inflammation.</li><li><strong>Therapies targeting the microbiome</strong> — including diet, probiotics, and adsorbents — offer a promising path forward.</li></ul><h3>📚 References</h3><ol><li>Vaziri ND, et al. <em>Kidney Int</em>. 2013;83(2):308–315.</li><li>Ramezani A, Raj DS. <em>JASN</em>. 2014;25(4):657–670.</li><li>Niwa T. <em>J Ren Nutr</em>. 2010;20(5 Suppl):S2–S6.</li><li>Vanholder R, et al. <em>Kidney Int</em>. 2003;63(5):1934–1943.</li><li>Tang WHW, et al. <em>Circ Res</em>. 2015;116(3):448–455.</li><li>Koppe L, et al. <em>Toxins (Basel)</em>. 2015;7(10):3792–3813.</li><li>Krishnamurthy VM, et al. <em>Kidney Int</em>. 2012;81(3):300–306.</li><li>Miyazaki T, et al. <em>Kidney Int Suppl</em>. 2000;78:S67–S70.</li><li>Wang X, et al. <em>Theranostics</em>. 2020;10(15):6844–6858.</li></ol><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*gN205KQ9d0rv_xE-JKWyMw.png" /></figure><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=280e27f73aee" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>